ARWR vs. XBI

In the year-to-date period, ARWR achieves a -30.69% return, which is significantly lower than XBI's -15.17% return. Over the past 10 years, ARWR has outperformed XBI with an annualized return of 7.61%, while XBI has yielded a comparatively lower 0.30% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ARWR Sharpe Ratio is -0.71, which is lower than the XBI Sharpe Ratio of -0.51. The chart below compares the historical Sharpe Ratios of ARWR and XBI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

ARWR has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.18%.

The maximum ARWR drawdown since its inception was -99.83%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for ARWR and XBI. For additional features, visit the drawdowns tool.

Arrowhead Pharmaceuticals, Inc. (ARWR) has a higher volatility of 21.38% compared to SPDR S&P Biotech ETF (XBI) at 11.38%. This indicates that ARWR's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.